Harmony Biosciences Reports Data For Pitolisant In The Treatment Of Excessive Daytime Sleepiness And Fatigue In Myotonic Dystrophy Type 1; The Primary Efficacy Endpoint Was The Change From Baseline To Week 11 In Daytime Sleepiness Scale Score; Secondary Efficacy Endpoints Was Also Greater For Pitolisant Versus Placebo
$HRMY
Biotechnology: Pharmaceutical Preparations
Health Care
Harmony Biosciences (NASDAQ:HRMY) presented data from its Phase 2 signal detection study showing that pitolisant reduced excessive daytime sleepiness (EDS) and fatigue in adults with Myotonic dystrophy Type 1 (DM1).